序号 |
标题 |
次数 |
作者 |
发布时间 |
82486 |
3,6-双(2-甲氧基苯基)-1,2-二氢-1,2,4,5-四嗪(2-MDHT);3,6-bis(2-methoxyphenyl)-1,2-dihydro-1,2,4,5-tetrazine |
131 |
WYQ |
2024-12-03 |
82487 |
3,6-二甲基-1,2,4,5-四嗪;3,6-Dimethyl-1,2,4,5-tetrazine |
130 |
WYQ |
2024-12-03 |
82488 |
3,3'-偶氮(6-氨基-1,2,4,5-四嗪);3,3'-Azobis(6-amino-1,2,4,5-tetrazine)(DAAT) |
158 |
WYQ |
2024-12-03 |
82489 |
3,6-d二肼基-1,2,4,5-四嗪(DHT) |
117 |
WYQ |
2024-12-03 |
82490 |
DOTA-D-phe1-Tyr3-奥曲肽 ,Ga-68-DOTA-TATE |
97 |
wyh |
2024-12-03 |
82491 |
DOTA-cCCK,DOTA偶联胆囊收缩素(CCK)受体 |
122 |
wyh |
2024-12-03 |
82492 |
3,6-d氨基-1,2,4,5-四嗪(DATZ) |
111 |
WYQ |
2024-12-03 |
82493 |
3-d氨基-6-(3,5-二甲基乙基吡唑-1-基)-1,2,4,5-四嗪(ADMPT) |
133 |
WYQ |
2024-12-03 |
82494 |
[DOTA]LTT-SS28 ,生长抑素模拟物 |
144 |
wyh |
2024-12-03 |
82495 |
DOTA-minigastrin (CP04) , DOTA-小胃泌素(CP04) |
150 |
wyh |
2024-12-03 |
82496 |
DOTA-rhuEpo ; DOTA-酰肼偶联rhuEpo |
92 |
wyh |
2024-12-03 |
82497 |
1,2,4,5-四嗪 , 化学式:C2H2N4 |
178 |
WYQ |
2024-12-03 |
82498 |
DOTA-Benerotide ;靶向生长抑素受体 |
87 |
wyh |
2024-12-03 |
82499 |
1,2,4,5-Tetrazines by Palladium Catalysis(钯催化1,2,4,5-四嗪的合成) |
100 |
WYQ |
2024-12-03 |
82500 |
5-苯基-1,2,4-三嗪-3-胺为例,为C9H8N4 |
98 |
WYQ |
2024-12-03 |
82501 |
DOTA-PEG-LA-AuNP,DOTA-PEG-硫辛酸修饰纳米金纳米粒子 |
116 |
wyh |
2024-12-03 |
82502 |
3,6-二(吡啶-2-基)-1,2,4,5-四嗪(pytz) |
147 |
WYQ |
2024-12-03 |
82503 |
HYNIC-PEG11-Tz;联肼尼克酰胺-十一聚乙二醇-四嗪;HYNIC-PEG11-Tetrazine |
98 |
WYQ |
2024-12-03 |
82504 |
DOTA-NT肽偶联金纳米粒子 ,DOTA-NT-AuNPs |
104 |
wyh |
2024-12-03 |
82505 |
[Zr-89]Zr-DFO-PEG5-Tz;[Zr-89]Zr-DFO-PEG5-Tetrazine |
107 |
WYQ |
2024-12-03 |
82506 |
MeTz-NOTA-RGD;甲基四嗪-大环配体-多肽 |
147 |
WYQ |
2024-12-03 |
82507 |
DOTA-Tyr(3)-奥曲肽, DOTA-Tyr(3)-Octreotide |
80 |
wyh |
2024-12-03 |
82508 |
AgNPs–pytz(3,6-二(吡啶-2-基)-1,2,4,5-四嗪包覆的银纳米粒子) |
100 |
WYQ |
2024-12-03 |
82509 |
3,6-di(pyridin-2-yl)-1,2,4,5-s-tetrazine (pytz,3,6-二(吡啶-2-基)-1,4-二氢-1,2,4,5-四嗪) |
124 |
WYQ |
2024-12-03 |
82510 |
DOTA-叶酸偶联物,DOTA-Folate |
131 |
wyh |
2024-12-03 |
82511 |
CQDs-DOTA-Yb,镱-DOTA螯合物功能化碳量子点 |
109 |
wyh |
2024-12-03 |
82512 |
3,6-dihydrazino-s-tetrazine (DHT,3,6-二肼基-s-四嗪) |
120 |
WYQ |
2024-12-03 |
82513 |
BCN-PEG-PAMAM ,环丙烷环辛炔-聚乙二醇-聚酰胺 |
108 |
zyl |
2024-12-03 |
82514 |
(DNAZTzDMP)2Ni(H2O)2][NO3]2;3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物 |
108 |
WYQ |
2024-12-03 |
82515 |
AB1-HLys-DOTA,DOTA偶联阳离子肽 |
102 |
wyh |
2024-12-03 |
82516 |
PAMAM-PEG-CKAAKN 树枝状大分子聚酰胺胺-聚乙二醇-CKAAKN多肽 |
105 |
zyl |
2024-12-03 |
82517 |
(NH2TzDMP)3Ni][NO3]2;3-氨基-6-(3,5-二甲基吡唑)四嗪配合物 |
87 |
WYQ |
2024-12-03 |
82518 |
(DNAZTzDMP)2Co(H2O)2;3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物 |
128 |
WYQ |
2024-12-03 |
82519 |
DOTA-1-nal 3-奥曲肽,Ga-DOTA-1-Nal3-octreotide |
76 |
wyh |
2024-12-03 |
82520 |
PAMAM-PEG-SP94 树枝状大分子聚酰胺胺-聚乙二醇-SP94多肽 |
106 |
zyl |
2024-12-03 |
82521 |
[(DNAZTzDMP)2Co(H2O)2](3-(3,3'-二硝基氮杂环丁烷)-6-(3,5-二甲基吡唑)四嗪配合物) |
135 |
WYQ |
2024-12-03 |
82522 |
LLP2A-DOTA-PEG(2000), LLP2A-DOTA-聚乙二醇(2000) |
95 |
wyh |
2024-12-03 |
82523 |
[(NH2TzDMP)2Co(H2O)(NO3)][NO3](3-氨基-6-(3,5-二甲基吡唑)四嗪配合物) |
92 |
WYQ |
2024-12-03 |
82524 |
3-(3,3'-dinitroazetidine)-6-(3,5-dimethylpyrazole)tetrazine(DNAZTzDMP) |
107 |
WYQ |
2024-12-03 |
82525 |
PAMAM-PEG-PTP 树枝状大分子聚酰胺胺-聚乙二醇-PTP多肽 |
99 |
zyl |
2024-12-03 |
82526 |
DOTA-SSTR;DOTA修饰生长抑素受体SSTR |
154 |
wyh |
2024-12-03 |
82527 |
NOTA-PEG(7)-Tz;大环化合物-七聚乙二醇-四嗪;NOTA-PEG(7)-Tetrazine |
116 |
WYQ |
2024-12-03 |
82528 |
PAMAM-PEG-RGDS 树枝状大分子聚酰胺胺-聚乙二醇-RGDS多肽 |
101 |
zyl |
2024-12-03 |
82529 |
PEGylated tetrazine;PEG4-Tz;聚乙二醇化四嗪;PEGylated Tz |
144 |
WYQ |
2024-12-03 |
82530 |
DOTA-ZOL, DOTA-唑来膦酸 |
94 |
wyh |
2024-12-03 |